PEGASUS: APL-2 for PNH Patients Being Treated with Exculizumab
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

PEGASUS: APL-2 for PNH Patients Being Treated with Exculizumab

Sponsor: Apellis Pharmaceuticals, Inc.

Protocol APL2-302: A study of APL-2 in patients with Paroxysmal Nocturnal Hemoglobinuria whose hemoglobin is less than 10.5 despite treatment with eculizumab for at least 3 months.